Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors

Area of Science:

• Oncology
• Immunology
• Computational Biology

Background:

• Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an immune checkpoint inhibiting T cell activity.
• Bromo- and Extra-Terminal (BET) inhibitors regulate oncogene expression and have shown anti-cancer effects.
• Combination therapies are crucial for improving cancer treatment efficacy.

Purpose of the Study:

• To develop a mathematical model for the combined therapy of BET inhibitors and CTLA-4 inhibitors in cancer treatment.
• To analyze the relationship between drug dosage and tumor volume reduction.
• To investigate the impact of combination therapy on myeloid-derived suppressor cells (MDSCs) and TNF-α levels.

Main Methods:

• Development of a mathematical model simulating cancer treatment.
• Analysis of drug-dose response relationships.
• Inclusion of factors like MDSCs and TNF-α to predict side effects.

Main Results:

• The mathematical model demonstrates a positive correlation between the doses of BET inhibitors and CTLA-4 inhibitors, and decreased tumor volume.
• Increased drug dosage leads to a reduction in tumor size.
• The model also predicts effects on MDSCs and TNF-α, potentially indicating gastrointestinal side effects.

Conclusions:

• Combined BET inhibitor and CTLA-4 inhibitor therapy shows promise for cancer treatment, with synergistic effects on tumor reduction.
• The mathematical model provides a framework for optimizing dosage and predicting potential side effects.
• Further research into the mechanisms and clinical application of this combination therapy is warranted.